(MENAFN- Trend News Agency)
Japan's Shionogi & Co Ltd said on Wednesday its oral treatment
for COVID-19 demonstrated a significant reduction in symptoms
compared to a placebo in a Phase III trial in Asia, reports citing .
The drug, a protease inhibitor known as ensitrelvir, met its
primary endpoint in a trial conducted among predominantly
vaccinated patients with mild to moderate cases of COVID-19, the
company said in a statement.
Regulatory authorities in Japan previously denied emergency
approval for use of the pill, saying they wanted to see more data
on its effectiveness. read more
Shionogi has global aspirations for the drug, also known as
S-217622 and by the brand name Xocova, which would compete with
COVID-19 pills from U.S. Pfizer Inc and Merck & Co Inc (MRK.N) that
have already been approved in Japan and elsewhere.
The company has signed an agreement to sell about a million
doses to the government, pending the drug's approval.
MENAFN28092022000187011040ID1104935824
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.